Medical Practice Valuation 2026 Guide
In today’s market, most professional buyers (private equity platforms, health systems, and strategic consolidators) price practices on adjusted EBITDA and apply a multiple dependent on many factors, including specialty and location. While you can’t change those items, multiples are sensitive to five forces you can influence: quality of earnings, scale, ancillaries, payer mix, and credible growth.
The best multiples are achieved through buyer competition, so when you are ready, it is important to market your practice through a structured process.
This article translates current market benchmarks into practical, table-driven takeaways. Treat the ranges as guideposts, not promises; your value will track the quality of earnings you can prove during diligence and buyer/seller dynamics unique to each transaction.
All valuation guidance is based on cited sources and internal knowledge. Actual pricing varies with each transaction and is based on many factors. Thus, information in this article is intended for educational purposes only and is not a guarantee of any outcome.
What you’ll learn in this article:
Buyers base valuations on adjusted EBITDA, making clean financials and credible add-backs essential to proving earnings.
Practices reaching $5M+ in EBITDA often qualify as platforms, earning 2–4× higher multiples than smaller add-ons.
A strong commercial or cash-pay mix and owned ancillaries, such as ASCs or cath labs, can lift valuations by several turns.
Multiples vary by specialty, with cardiology, ophthalmology, and large DSOs leading the 2026 ranges.
Early preparation (accurate financials, growth plans, and compliance readiness) remains the most reliable path to top-quartile outcomes.
Valuation Basics: Maximizing EBITDA and Multiples
Before comparing specialties, anchor on the core equation. Buyers pay for the enterprise value (EV) of a practice’s cash flows on a last-twelve-months basis, not last year’s tax return. That’s why your normalization (owner comp resets, one-time expenses, and related-party adjustments) matters as much as the headline multiple. Use this section as a quick formula reference before you dive into sector ranges.
EV ≈ Adjusted EBITDA × Sector/Scale Multiple
What to normalize first:
Reset above-market owner compensation to fair-market provider rates
Remove personal/non-recurring expenses and pandemic anomalies
Align related-party rent to market, note any below-market leases ending soon
Pro forma necessary hires (e.g., replacing a retiring producer) and de novo costs
Consider pro forma adjustments for new providers, new locations, payor changes, and similar growth initiatives
Valuation Approaches in Healthcare M&A
Medical practice value can be calculated in three ways:
| Market-Based Approach | Income-Based Approach | Income-Based Approach |
|---|---|---|
| Compares your practice to recent sales of similar companies, typically applying EBITDA or revenue multiples. Most healthcare M&A transactions use this method. | Projects future cash flows and discounts them to present value. | Values tangible and intangible assets separately, subtracting liabilities. This is used for small or underperforming practices where earnings are limited or negative. |
Most physician and dental practice valuations use the first approach, focusing on recent transaction comps. Buyers may also consider the discounted cash flow model, especially when entering a new specialty.
Typical EBITDA Multiples by Healthcare Vertical (U.S., 2025–2026)
This table provides the starting point most buyers use when pricing deals. It consolidates observed ranges across six active healthcare services verticals. Use it to sanity-check your current position before making adjustments for size, growth, or ancillaries.
| Healthcare sector | Typical EBITDA multiples | Notes that drive the range |
|---|---|---|
| Physician practices (medical) | ~5×–9× small groups; ~10×–12× scaled multi-site | Can go higher for $5M+ EBITDA, diversified bench, ancillaries, dense coverage |
| Dental groups (DSO) | ~5×–11× | Premiums for multi-location pedo/ortho, OMS; lower for single-site <$1M EBITDA |
| Behavioral health | ~3×–8× small clinics; ~5×–10× mid-size/multi-site; low-teens for elite platforms | In-network mix, continuum of care, accreditation, multi-site, multi-state ops |
| Medical spa/aesthetics | ~3×–6× small; ~5×–8× mid-size; ~7×–12× scaled chains; 15×+ outliers | Membership revenue, brand strength, and multi-state replication |
*If your practice sits at the upper end of a range, that’s usually because you also score well on scale, growth, payer mix, and ancillaries below. Actual pricing varies with each transaction based on many factors. Intended for educational purposes only and not a guarantee of any outcome.
The Platform Premium by Size Band
Multiples don’t rise linearly with EBITDA: they tend to step-change at certain thresholds (often reflecting management depth, infrastructure, lender readiness). Use this table to understand why adding EBITDA dollars can create 2–4 extra turns of multiple, not just more earnings.
| Adjusted EBITDA | Typical buyer view | Cross-vertical valuation tendency |
|---|---|---|
| <$1M | Physician-to-physician or local tuck-in | Asset value to ~5×–6× |
| $1M–$3M | Add-on for an existing platform | ~5×–9× |
| $3M–$7M | Emerging platform with partial infrastructure | ~7×–11× |
| $7M+ | Established platform with scale and systems | ~9×–13×+ |
Payer Mix and Ancillaries: Levers That Move Your Multiple
Buyers price durability. Commercial and cash-pay revenue is more defensible than government-dependent books, and procedure-rich ancillaries lift margin and predictability. Use this table to prioritize the levers with the highest “multiple elasticity.”
| Factor | Directional impact on multiple | Why it moves value |
|---|---|---|
| ≥70% commercial or meaningful cash-pay | ↑ | Better rates, fewer denials, steadier collections |
| Heavy Medicaid / state funding | ↓ | Rate ceilings, budget risk |
| In-network vs out-of-network | ↑ for in-network | Contracted reimbursement is auditable and scalable |
| Owned ASC / surgery capacity | ↑ (often +1–2 turns) | Procedure margin stabilizes EBITDA |
| Ancillaries (imaging, lab, pharmacy) | ↑ | Revenue diversity and higher blended margin |
| Over-reliance on one star provider | ↓ | Concentration and succession risk |
What Pushes You to The High or Low End By Specialty
Every vertical has premium catalysts and discount flags. This table compiles the pattern recognition buyers commonly apply within each niche, allowing you to preempt issues in diligence and highlight strengths in your CIM.
| Vertical | Premium drivers | Common discounts |
|---|---|---|
| Physician groups | $3M+ EBITDA, diversified bench, dense referral base, ancillaries | Shrinking visits, single-doc reliance, reimbursement overhang |
| Dental (DSO) | Multi-location scale, pedo/ortho, OMS, strong hygiene recall, growth plan | Heavy Medicaid, flat production, owner-centric ops |
| Behavioral health | In-network mix, continuum of care, JCAHO/CARF, multi-state ops | OON dependence, staffing instability, regulatory history |
| Ophthalmology | ASC ownership, retina services, multiple MDs incl. younger partners | Senior partner succession |
| Women’s health | Imaging, surgery, fertility, midwifery, menopause programs | OB call burden without coverage, med-mal spikes |
| Medspa | Membership revenue, multi-market brand, de-novo playbook | Owner-operator dependence, transactional revenue only |
Sector Spotlights (What The Numbers Mean In Practice)
These short profiles translate ranges into deal reality: how buyers talk about risk, what they underwrite as upside, and where they stretch.
Physician Practices: Multi-Specialty & Medical Groups
Independent groups most often transact in the mid- to high-single-digit EBITDA arena. Crossing into $5M+ EBITDA with ancillary revenue and recruiting momentum often shifts the buyer pool from “local add-on” to “platform-ready,” where multiples can move toward ~10×–12×.
Pure physician-to-physician sales in unconsolidated fields can clear at a lower level, sometimes on revenue or asset value, when EBITDA is thin.
Value Drivers:
Documented growth path (de-novos, extender hiring, service-line adds)
Durable referral base and payer diversity
Clean add-backs and month-over-month KPI stability
Valuation Challenges:
Single-key producer nearing retirement with no succession plan
Flat or declining visit trends going into marketing
Unvetted add-backs that won’t survive diligence
Dental Support Organization (DSO)
DSOs remain active buyers. Healthy multi-location groups commonly land ~7×–11× with pedo/ortho and Oral and Maxillofacial Surgery (OMS) at the upper end. Single-site practices with an EBITDA of under $1 million typically trade at a lower valuation unless they are specialty “gems.”
Value Drivers:
Multi-office density, provider leverage beyond a single star, robust hygiene recall
A concrete clinic expansion plan (hours, chairs, de novos) with historical proof of execution
Valuation Challenges:
Heavy Medicaid exposure without a path to mix improvement
Flat production and high attrition masked by marketing specials
Behavioral Health
Ranges are wide by sub-sector. Small clinics often trade ~3×–8×; mid-size regional operators with in-network contracts and a continuum of care typically see ~5×–10×; the largest, fastest-growing autism/eating-disorder platforms can still achieve low teens in 2026.
Major platforms have achieved very high valuations (e.g., Nautic Partners acquired Proud Moments ABA, a Boston-based autism therapy provider, in a deal valued at $425M, with price/EBITDA at 21.3x, according to VMG health).
Value Drivers:
In-network commercial mix
Multi-level programs
Strong outcomes
Accreditation
Multi-state infrastructure and a repeatable new-site playbook
Valuation Challenges:
OON dependence
Staffing churn
Prior compliance issues
Ophthalmology
The market continues to prize ASC-enabled eye care. Small non-ASC practices cluster ~5×–7×; mid-size groups rise to ~7×–9×; high-MD count platforms can reach ~10× or above. Retina-only practices can achieve additional competition from specialty buyers.
Value Drivers:
ASC margin stability
Diversified revenue (clinic, surgery, optical)
Younger physicians in the mix
Valuation Challenges:
Medicare rate sensitivity without offsetting commercial mix (though a higher Medicare payor mix expected within the specialty)
Senior-heavy partner group without a recruiting pipeline
Women’s Health (OB/GYN)
Sizable, diversified groups commonly achieve high-single-digit to low-double-digit multiples, especially with imaging, surgery, fertility, or menopause programs already in place (or with a credible build-out plan).
Valuation Drivers:
Comprehensive service stack, predictable prenatal volumes, and post-acute programs
Strong governance and call-coverage models that mitigate burnout risk
Valuation Challenges:
High med-mal cost trend, heavy OB burden with narrow call pool
Medical Spas & Aesthetics
Aesthetics is cash-pay and brand-driven. Single-site clinics often clear ~3×–6×; regional chains ~5×–8×; scaled, multi-state brands may achieve ~7×–12×, with rare outliers above on forward growth.
Valuation Drivers:
Membership/subscription revenue, high repeat rates, multi-market brand equity
A demonstrated de-novo replication playbook and device ROI discipline
Valuation challenges:
Owner-operator key-person risk, purely transactional revenue, device vendor overhang
How Buyers Evaluate Risk and Upside
Buyers ultimately assess not just what a practice earns today, but how reliable and transferable those earnings are. In diligence, this typically comes down to a few consistent areas of focus:
| Evaluation Area | What Buyers Look For | Why It Matters |
|---|---|---|
| Earnings Quality | Clean financials, clear add-backs, consistent margins | Reduces uncertainty and supports valuation confidence |
| Provider Model | Defined roles, productivity visibility, and reduced single-provider reliance | Improves continuity post-transaction |
| Operational Structure | Documented workflows, scheduling discipline, billing visibility | Signals scalability and ease of integration |
| Growth Visibility | Clear expansion paths (providers, locations, services) | Supports forward-looking underwriting |
| Compliance & Documentation | Organized records, credentialing, and reporting | Minimizes diligence friction and delays |
This lens often explains why two practices with similar EBITDA can receive different valuations. The practice that is easier to understand, validate, and transition will generally command stronger buyer interest.
Common Gaps That Can Impact Valuation
Even strong practices can face valuation pressure if key areas are underdeveloped or unclear. The following issues are frequently encountered during the sale process:
Unclear financial adjustments: Inconsistent or poorly documented add-backs can lead buyers to discount EBITDA or require additional diligence.
Limited visibility into operations: Lack of reporting around scheduling, provider productivity, or case mix can make performance harder to validate.
Overreliance on a single provider: Practices heavily dependent on one individual may raise concerns around continuity and transition risk.
Informal or undefined growth plans: General ideas around expansion are less impactful than clearly outlined, actionable opportunities.
Disorganized documentation: Missing or incomplete records can slow diligence and create avoidable friction late in the process.
Addressing these areas in advance can help maintain momentum, reduce buyer concerns, and support a more efficient transaction process.
How Buyers Underwrite, and Where You Can Influence Outcomes
This section explains why two similar practices can price two turns apart. Use it as a pre-diligence checklist to move your story from the middle to the top of the range.
What lifts your multiple:
Profitability & scale: absolute EBITDA and margin quality
Operational durability: payer diversity, referral stability, repeatable KPIs
Growth clarity: funded de-novos, pipeline recruiting, and ancillaries with budgets
Competitive tension: a process that reaches all logical buyers in your niche
Strategic fit: solving a buyer’s footprint or service-line gap
What compresses it:
Declining visits/production going into the process
Unvetted add-backs or missing month-end discipline
Concentration in one payer, producer, or referral source
Readiness Roadmap
Thinking of marketing in the next 6–12 months? These are the moves that consistently convert into higher headline multiples and fewer retrades. Treat them as a checklist you can execute with your advisors well before buyer outreach.
What to do now:
Assemble 24–36 months of clean monthly financials with a defensible add-back schedule
Package payer mix, denial rates, collections KPIs, and throughput metrics
Build succession and recruiting plans for senior producers
Map growth initiatives (de-novos, ancillaries, ASC) with capex and timelines
Tighten compliance posture and accreditation; resolve any legacy issues
Align related-party real estate to fair market terms
Stand up a structured data room to control diligence
Putting It Together: Maximize EBITDA, Expand The Multiple, Protect Value
Valuation is the product of what you earn, how you earn it, and who is bidding. This article shows where your specialty tends to price; the levers and checklists show how to move up the curve. With thoughtful normalization, a crisp growth plan, and a competitive process targeting the right acquirers in your niche, it’s realistic to capture top-quartile outcomes, even in a cautious credit environment.
If you’d like more information, reach out to us here.
Sources:
Eric Yetter (FOCUS Investment Banking), “How to Value a Medical Practice: What Really Matters,” FOCUS Bankers (July 31, 2023) focusbankers.com
FOCUS Investment Banking – Healthcare Practice Management Updates (Ophthalmology 2024 Market Overview) focusbankers.com
Chip Fichtner, Large Practice Sales – “2024 Results and 2025 Practice Values (Dental)” (Jan. 9, 2025) largepracticesales.com
Scope Research – “Med Spa and Aesthetics Valuation Multiples and M&A Trends 2025,” (Updated Aug. 6, 2025) scoperesearch.co
Scope Research – “Behavioral Health: SUD Treatment Valuation Multiples and Trends 2025,” (May 7, 2025) scoperesearch.co
Scope Research – “Autism Services & Pediatric Therapy Valuation Multiples 2024,” (May 17, 2024) scoperesearch.co.
Cascade Partners, Vision Care Market Update (Ophthalmology multiples by practice size, 2023) cascade-partners.com
Physician Growth Partners, “State of Women’s Health Private Equity – Q1 2025” (White Paper) physiciangrowthpartners.com
Solic Capital, “Physician Practice Management Q4 2020 Update” (Women’s Health platform valuations) soliccapital.com.
